Glaucoma is a chronic neurodegenerative disease characterized by the progressive loss of retinal ganglion cells (RGCs). Mitochondrial DNA (mtDNA) alterations have been documented as a key component of many neurodegenerative disorders. However, whether mtDNA alterations contribute to the progressive loss of RGCs and the mechanism whereby this phenomenon could occur are poorly understood. We investigated mtDNA alterations in RGCs using a rat model of chronic intraocular hypertension and explored the mechanisms underlying progressive RGC loss. We demonstrate that the mtDNA damage and mutations triggered by intraocular pressure (IOP) elevation are initiating, crucial events in a cascade leading to progressive RGC loss. Damage to and mutation of mtDNA, mitochondrial dysfunction, reduced levels of mtDNA repair/replication enzymes, and elevated reactive oxygen species form a positive feedback loop that produces irreversible mtDNA damage and mutation and contributes to progressive RGC loss, which occurs even after a return to normal IOP. Furthermore, we demonstrate that mtDNA damage and mutations increase the vulnerability of RGCs to elevated IOP and glutamate levels, which are among the most common glaucoma insults. This study suggests that therapeutic approaches that target mtDNA maintenance and repair and that promote energy production may prevent the progressive death of RGCs.
a b s t r a c t a r t i c l e i n f o Introduction
Glaucoma is a complex, multifactorial neurodegenerative disease (Gupta and Yucel, 2007) . Progressive retinal ganglion cell (RGC) death is a primary contributor to the loss of vision, and elevated intraocular pressure (IOP) is a major risk factor (Buckingham et al., 2008; Kwon et al., 2009) . Factors known to be involved in glaucoma pathogenesis include mechanical stress due to elevated IOP, axonal transport failure, reduced blood flow to the retina, reperfusion injury, oxidative stress, glutamate excitotoxicity, aberrant immune response, and glial dysfunction (Wax et al., 2008 ) (Almasieh et al., 2012 . However, these factors have not yet provided a plausible explanation for why the adequate control of IOP only delays rather than halts RGC loss and glaucoma progression (Cantor, 2006; Osborne, 2010 ). An in-depth understanding of the molecular basis of accelerated RGC death, which can occur months or years after the initiation of glaucoma (Osborne, 2010) , is critical for the development of new therapeutic strategies for protecting RGCs and the optic nerve in glaucoma patients.
Mitochondrial DNA (mtDNA) damage and mutations have been documented as a key component of many neurodegenerative disorders. mtDNA is much more susceptible than nuclear DNA (nDNA) to damage because of the lack of DNA protection by histones and the proximity to reactive oxygen species (ROS) generated by the mitochondrial respiratory chain (Mambo et al., 2003) . Unrepaired DNA damage can result in mutations (Mambo et al., 2003) . These alterations (damage and Abbreviations: mtDNA, mitochondrial DNA; POLG, DNA polymerase gamma; OGG1, 8-oxoguanine DNA glycosylase; MYH, DNA glycosylase MutY homolog; ND4, NADH dehydrogenase subunit 4; ND5, NADH dehydrogenase subunit 5; ND6, NADH dehydrogenase subunit 6; cytB, cytochrome b; MAPR, mitochondrial ATP production rate; ROS, reactive oxygen species; EVC, episcleral vein cauterization; shRNAs, short-hairpin RNAs; PCR, polymerase chain reaction; LX-PCR, long-extension PCR; FG, Fluoro-Gold; DPBS, Dulbecco's phosphate-buffered saline; BSA, bovine serum albumin; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.
